California-based real-world data platform Atropos Health announced it completed a strategic financing round with participation from Sumitomo Corporation Venture Group’s Presidio Ventures, Samsung Next, Audere Capital, Gaingels and other investors.
WHAT IT DOES
Atropos Health offers AI innovations, evidence generation, analytics augmentation and data evaluation to help physicians access real-world evidence to guide clinical decisions and research.
Additionally, the company’s clinical informatics services, dubbed Green Button, provide publication-grade observational study reports within 48 hours, based on a user’s clinical questions.
It touts its platform as being able to navigate data restrictions in international markets. Atropos says it will use the funds to expand its reach globally, initially focusing on customers in Brazil and Japan.
“Lack of representation in clinical trials leads to the problem of ‘The evidence Gap’. This problem persists in the U.S. but is perhaps even more pronounced globally. With the addition of funding from partners Samsung Health and Sumitomo/Presidio, Atropos will bring our evidence generation platform around the world to ultimately provide more personalized evidence for care based on millions of patients like them, which can positively impact care,” Dr. Brigham Hyde, CEO and cofounder of Atropos Health, told MobiHealthNews in an email.
MARKET SNAPSHOT
Last year, Atropos scored $14 million in a Series A funding round.
In August, the company announced it appointed a life sciences advisory board to move into the life sciences sector, allowing companies to maximize real-world datasets for protocol feasibility, cohort analysis, unmet needs, hypothesis testing, treatment pathways, regulatory initiatives, label expansions and patient journeys.
The company announced a partnership with data sharing technology platform Datavant in June, which would provide each company’s members access to the other company’s offerings, and last year disclosed its collaboration with Syntegra, in which its Green Button would leverage the healthcare data platform’s synthetic data.
Another company in the healthcare data space is Komodo Health, which offers a platform that collects de-identified patient encounters that can be used to create software for life science companies and insurers to determine how patient experiences connect to health outcomes.
